Illumina, Inc. (NASDAQ:ILMN) SVP Charles Dadswell sold 1,609 shares of the firm’s stock in a transaction dated Thursday, August 3rd. The shares were sold at an average price of $197.00, for a total value of $316,973.00. Following the transaction, the senior vice president now owns 9,037 shares of the company’s stock, valued at approximately $1,780,289. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
Charles Dadswell also recently made the following trade(s):
- On Monday, July 3rd, Charles Dadswell sold 145 shares of Illumina stock. The shares were sold at an average price of $174.24, for a total value of $25,264.80.
- On Monday, June 5th, Charles Dadswell sold 145 shares of Illumina stock. The shares were sold at an average price of $184.75, for a total value of $26,788.75.
Illumina, Inc. (NASDAQ ILMN) opened at 197.61 on Wednesday. The stock has a market capitalization of $28.85 billion, a price-to-earnings ratio of 39.65 and a beta of 0.83. Illumina, Inc. has a 12 month low of $119.37 and a 12 month high of $199.86. The stock’s 50 day moving average is $176.74 and its 200-day moving average is $172.43.
Illumina (NASDAQ:ILMN) last posted its earnings results on Tuesday, August 1st. The life sciences company reported $0.82 earnings per share for the quarter, beating the consensus estimate of $0.68 by $0.14. The company had revenue of $662 million for the quarter, compared to analyst estimates of $642.38 million. Illumina had a net margin of 30.27% and a return on equity of 19.69%. Illumina’s revenue was up 10.3% on a year-over-year basis. During the same period in the previous year, the business posted $0.86 EPS. On average, equities research analysts expect that Illumina, Inc. will post $3.65 earnings per share for the current year.
ILLEGAL ACTIVITY WARNING: “Charles Dadswell Sells 1,609 Shares of Illumina, Inc. (NASDAQ:ILMN) Stock” was posted by StockNewsTimes and is the sole property of of StockNewsTimes. If you are accessing this report on another website, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The legal version of this report can be accessed at https://stocknewstimes.com/2017/08/09/charles-dadswell-sells-1609-shares-of-illumina-inc-nasdaqilmn-stock.html.
ILMN has been the subject of a number of research analyst reports. Piper Jaffray Companies restated an “overweight” rating and set a $187.00 price objective (up previously from $170.00) on shares of Illumina in a research report on Friday, April 14th. Vetr lowered Illumina from a “strong-buy” rating to a “buy” rating and set a $197.84 price objective for the company. in a research report on Wednesday, June 21st. Barclays PLC restated a “hold” rating and set a $150.00 price objective on shares of Illumina in a research report on Wednesday, July 19th. BidaskClub lowered Illumina from a “sell” rating to a “strong sell” rating in a research report on Tuesday, July 25th. Finally, Cowen and Company restated an “outperform” rating and set a $200.00 price objective on shares of Illumina in a research report on Wednesday, April 26th. Two analysts have rated the stock with a sell rating, ten have given a hold rating and eleven have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus price target of $177.01.
A number of institutional investors have recently bought and sold shares of ILMN. Advocacy Wealth Management Services LLC purchased a new position in Illumina during the first quarter valued at $102,000. Gemmer Asset Management LLC raised its position in Illumina by 5.7% in the first quarter. Gemmer Asset Management LLC now owns 686 shares of the life sciences company’s stock valued at $117,000 after buying an additional 37 shares during the last quarter. Advisory Services Network LLC purchased a new position in Illumina during the first quarter valued at $117,000. Penserra Capital Management LLC raised its position in Illumina by 13.0% in the second quarter. Penserra Capital Management LLC now owns 884 shares of the life sciences company’s stock valued at $153,000 after buying an additional 102 shares during the last quarter. Finally, Paradigm Asset Management Co. LLC raised its position in Illumina by 5.6% in the second quarter. Paradigm Asset Management Co. LLC now owns 950 shares of the life sciences company’s stock valued at $165,000 after buying an additional 50 shares during the last quarter. Institutional investors own 93.81% of the company’s stock.
About Illumina
Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.
Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
